Oncolytics Biotech (ONCY) has disclosed a new risk, in the Corporate Activity and Growth category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Oncolytics Biotech faces significant business risk due to the uncertainty of its ability to remain a going concern over the next twelve months. Although the company has cash reserves to sustain operations until the third quarter of 2025, its survival hinges on securing additional financing through equity or strategic partnerships. The challenges of raising capital in the micro-cap market and potential inability to cut expenditures further exacerbate this risk, casting doubt on its financial stability. Failure to obtain necessary funding could necessitate substantial adjustments to its financial positions, impacting asset valuations and liabilities.
Overall, Wall Street has a Moderate Buy consensus rating on ONCY stock based on 1 Buy.
To learn more about Oncolytics Biotech’s risk factors, click here.